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Abstract	  
	  
Objectives:	  To	  contribute	  to	  current	  knowledge	  on	  the	  vascular	  risk	  of	  oestrogens.	  
	  
Materials	  and	  methods:	  A	  44-­‐year-­‐old	  woman	   received	  a	  11.25	  mg	  Leuprolide	  exteneded	   release	   injection	   to	   control	  
bleeding	   from	   a	   7	   cm	   uterine	   fibroid	   tumour;	   45	   days	   later,	   she	   had	   a	   stroke	   due	   to	   right	   frontal	   lobe	   ischaemia.	  
Thrombolysis	   induced	   complete	   remission.	   Three	   years	   previously,	   while	   taking	   a	   birth	   control	   pill,	   the	   patient	   had	  
suffered	   from	  a	  stroke	   that	   involved	  her	   left	   temporal	   lobe.	  She	  was	  heterozygous	   for	  Factor	  V	  R2	  H1299R	   locus	  and	  
homozygous	  for	  the	  4G/4G	  mutation	  of	  the	  PAI-­‐1	  gene.	  Even	  though	  her	  homocysteine	   level	  was	  normal,	   the	  patient	  
was	   homozygous	   for	   the	   MTHFR	   C677T	   mutation	   and	   although	   she	   had	   never	   had	   severe	   bleeding,	   she	   was	   also	  
homozygous	  for	  Factor	  XIII	  V34L.	  
	  
Results	   and	   conclusion:	   This	   patient’s	   prothrombotic	   condition	   could	   have	   been	   enhanced	   by	   leuprolide	   since	   its	  
stimulatory	  effect	  on	  oestrogen	  production	  would	  still	  have	  been	  minimally	  present	  at	  the	  time	  of	  cerebral	  thrombosis.	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Introduction	  
Stroke	   in	   young	   subjects	   is	   devastating.	  A	   structured	  programme	  of	   interventions	  has	   recently	   been	   implemented	   to	  
prevent	  it,	  to	  dissolve	  the	  thrombus	  during	  the	  acute	  phase	  before	  the	  ischaemia	  becomes	  irreversible	  and	  to	  avoid	  the	  
thrombogenic	   adverse	   effects	   of	   drugs	   and	   procedures	   [1].	   The	   present	   case	   addresses	   the	   latter	   type	   of	   effective	  
interventions.	  We	  herein	  describe	  a	  patient	  who	  suffered	  a	  stroke	  due	  to	  the	  administration	  of	  an	  LHRH	  analogue	  given	  
to	  curb	  chronic	  minor	  bleeding	  from	  a	  fibroid	  tumour	  of	  the	  uterus.	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Case	  description	   	  
A	  44-­‐year-­‐old	  woman	  had	  a	  sudden	  onset	  of	  dysarthria,	  left	  faciobrachial	  motor	  weakness	  and	  limb	  ataxia	  (NIHSS=5).	  On	  
admission	  to	  hospital,	  an	  emergency	  brain	  CT	  scan	  showed	  two	  old	  foci	  of	  ischaemia	  in	  her	  left	  parietal	  area	  and	  right	  
cerebellum.	   Thrombolysis	   was	   performed	   according	   to	   the	   established	   guidelines	   with	   rtPA	   0.9	   mg/kg	   [1].	   The	  
symptoms	  abated	  progressively	  during	  the	  ensuing	  four	  days.	  The	  patient	  was	  in	  sinus	  rhythm.	  A	  cerebral	  angiography	  
performed	   the	   day	   after	   thrombolysis	   disclosed	   no	   vascular	   obstruction,	   while	   an	   NMR	   2	   days	   later	   showed	   an	  
ischaemic	   change	   involving	   her	   right	   cortical	   and	   subcortical	   frontal	   sylvian	   area.	   Trans-­‐oesophageal	   echocardiogram	  
and	   colour-­‐flow	   duplex	   ultrasound	   examinations	   ruled	   out	   cardiac	   and	   aortic	   arch	   abnormalities	   as	   well	   as	   carotid	  
plaques.	  Past	  history	  revealed	  that	  the	  patient	  had	  been	  chronically	  bleeding	  from	  a	  large	  7	  cm	  uterus	  fibroid	  tumour	  
that	  had	  been	  treated	  45	  days	  previously	  with	  an	  11.25	  mg	  Leuprolide	  Depot	  i.m.	  injection.	  Her	  former	  stroke	  in	  her	  left	  
parietal	  area	  had	  occurred	  3	  years	  earlier	  while	  she	  was	  taking	  an	  oestro-­‐progestinic	  birth	  control	  medication.	  During	  
the	  present	  event,	  her	  homocysteine	  blood	  level	  was	  5.6	  μM/l,	  D-­‐dimer	  511	  ng/ml	  (it	  fell	  to	  144	  in	  4	  days),	  C3c	  79	  mg/dl,	  
progesterone<0.2	  mU/ml,	   17β-­‐oestradiol	   107.5	  pg/ml,	   LH	   (Luteinizing	  hormone)	  3.7	  mUI/ml,	   FSH	   (Follicle	   stimulating	  
hormone)	   6.6	   mUI/ml,	   β-­‐HCG	   (Human	   chorionic	   gonadotropin)	   <0.1	   mUI/ml,	   Hb	   (Hemoblobin)	   8.5	   g/dl,	   ANA	  
(Antinuclear	  antibodies)	  test	  and	  LAC	  (Lupus	  anticoagulant)	  negative,	  coagulation	  protein	  C	  59%,	  free	  protein	  S	  172%,	  
serum	  iron	  42	  μg/dl,	  transferrin	  247	  mg/dl	  and	  ferritin	  16	  ng/ml.	  Her	  home	  medications	  were	  aspirin	  100	  mg	  q.d.,	  folic	  
acid	  5	  mg	  q.d.	  and	  iron	  sulphate	  300	  mg	  p.o.,	  b.i.d.	  She	  was	  transfused	  with	  packed	  red	  cells	  to	  a	  Hb	  of	  10.5	  g/dl.	   	  
An	  exhaustive	  screening	  for	  prothrombotic	  abnormalities	  revealed	  the	  presence	  of	  the	  heterozygous	  mutation	  H1299R	  
of	  coagulation	  Factor	  V,	  the	  homozygous	  mutation	  4G/4G	  of	  PAI-­‐1	  and	  the	  homozygous	  mutation	  C677T	  of	  MTHR.	  The	  
patient	  was	  also	  a	  carrier	  of	  the	  homozygous	  mutation	  C34L	  of	  coagulation	  Factor	  XIII.	  
	  
Discussion	  
This	  patient	  was	  at	  risk	  of	  stroke	  as	  she	  had	  already	  experienced	  three	  ischaemic	  episodes	  before	  age	  45.	  The	  first	  two	  
ischaemic	   events	   were	   presumably	   due	   to	   the	   homozygous	   deficit	   of	   MTHFR,	   which	   preferentially	   affects	   arterial,	  
mainly	   cerebral,	   vessels,	   although	   the	  alteration	  of	   Factor	  V.	  The	  oestro-­‐progestin	   combination	  could	  have	  played	  an	  
adjuvant	   role.	   However,	   this	   most	   recent	   stroke	   occurred	   in	   the	   presence	   of	   a	   normal	   homocysteine	   serum	   level,	  
presumably	  due	  to	  the	  daily	  prophylaxis	  with	  folic	  acid,	  thus	  ruling	  out	  MTHFR	  as	  a	  causative	  factor.	   	  
After	  a	  Food	  and	  Drug	  Administration	  (FDA)	  review,	  LHRH	  analogues	  were	  introduced	  into	  the	  market	  without	  warning	  
against	  the	  occurrence	  of	  stroke.	  The	  post-­‐marketing	  clinical	  experience	  of	  these	  drugs	  found	  a	  small,	  approximately	  1%,	  
albeit	  statistically	  significant	   incidence	  of	  stroke,	  mainly	   in	  patients	  with	  diabetes	  mellitus,	  cardiovascular	  disease	  and	  
previous	   cerebral	   ischaemia.1	   The	   literature	   mentions	   mostly	   male	   patients	   treated	   with	   chemical	   castration	   for	  
prostate	  cancer.	  In	  contrast,	  our	  patient	  is	  a	  female	  treated	  for	  uterine	  bleeding	  caused	  by	  a	  fibroid	  tumour,	  one	  of	  the	  
indications	   listed	   for	   LHRH	   analogue	   use	   [2].	   These	   drugs	  may	   cause	   thrombosis	   because	   of	   the	   sudden	   upsurge	   of	  
oestradiol	   and	   progestin	   levels	   lasting	   10	   days	   after	   beginning	   their	   administration.	   Although	   the	   ischaemic	   event	  
occurred	  in	  our	  patient	  long	  after	  the	  initial	  oestrogen	  upsurge	  had	  faded	  away	  (i.e.,	  45	  days	  after	  the	  administration	  of	  
                                                   
1	   FDA	  warning	  on	  20	  October	  2010,	  in	  which	  manufacturers	  ”transient	  ischemic	  attack	  and	  paralysis”	  in	  the	  drug	  data	  sheet.	  This	  was	  due	  to	  the	  
results	  of	  an	  FDA	  investigation	  into	  these	  products.	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leuprolide),	  oestrogen	  levels	  would	  still	  have	  been	  elevated.	  It	   is,	  therefore,	  reasonable	  to	  hypothesize	  that	  the	  GHRH	  
still	  had	  a	  prothrombotic	  effect.	   	  
In	  a	  recent	  systematic	  review,	   it	  was	  proposed	  that	  the	  prolonged	  supraphysiological	   levels	  of	  oestrogen,	  released	  by	  
high-­‐dose	  pellet	   implants,	  were	  responsible	  for	  the	  detrimental	  effects	  of	  oestrogen.	  However,	   it	  also	  seems	  plausible	  
that	  the	  LHRH	  analogues	  presently	  marketed	  could	  act	  by	  some	  unknown	  direct	  effect	  on	  cerebral	  vessels	  of	  patients	  
who	  have	  already	  suffered	  from	  cerebral	  ischaemia,	  or	  who	  are	  affected	  by	  vascular	  and/or	  cardiovascular	  diseases,	  like	  
diabetes.	  In	  fact,	  Fujiki	  and	  co-­‐workers	  claim	  such	  a	  mechanism	  for	  the	  leuprolide-­‐associated	  stroke	  in	  a	  young	  Japanese	  
woman	  [3],	  suggesting	  the	  enhancement	  of	  vascular	  production	  of	  oxygen	  radicals.	  A	  similar,	  direct	  vascular	  effect	  was	  
demonstrated	   in	  a	  case	  of	  myocardial	   infarction	   [4].	  Although	  the	  mechanism	  of	  action	  of	  LHRH	  analogues	   in	  causing	  
brain	   ischemia	  must	  be	  considered	  unknown,	  the	  risks	  endowed	  with	  their	  administration	  must	  be	  considered	  real.	   It	  
therefore	   seems	   prudent	   to	   limit	   the	   administration	   to	   subjects	   without	   diabetes,	   cardiovascular	   disease,	   previous	  
ischaemic	  events	  and	  coagulation	  abnormalities	  favouring	  thrombosis.	  
	  
Learning	  Points	  
	  
• Leuprolide	  could	  be	  a	  risk	  factor	  for	  ischaemic	  stroke.	  
• Genetic	  prothrombotic	  abnormalities	  should	  be	  looked	  for	  in	  young	  patients	  with	  cryptogenic	  strokes.	  
• It	  seems	  prudent	  to	  avoid	   leuprolide	  use	   in	  subjects	  with	  diabetes,	  cardiovascular	  disease,	  previous	   ischaemic	  
events	  and	  coagulation	  abnormalities	  favouring	  thrombosis.	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